Overview

• White House spokesman Kush Desai said the administration is not actively discussing Section 232 tariffs on generic drugs, and Commerce officials indicated the probe is not expected to yield duties on generics.
• Advisers, including members of the Domestic Policy Council, warned that tariffs on low-cost generics could drive up U.S. prices and risk shortages, a key concern given India supplies about 47% of generic prescriptions filled in U.S. pharmacies.
• Multiple outlets reported President Trump will announce an AstraZeneca agreement featuring most‑favored‑nation pricing for Medicaid and direct sales via TrumpRx.gov, with the company committing roughly $50 billion to U.S. manufacturing and R&D.
• Pfizer’s finalized pact remains the template: about 50% discounts on many medicines through TrumpRx in 2026, MFN pricing for new drugs, MFN sales to state Medicaid programs, and a three‑year tariff reprieve tied to U.S. investment.
• The previously threatened 100% tariffs on branded drugs did not take effect on Oct. 1 and are serving as leverage in negotiations, while pharmacies and GoodRx are in talks with the administration about participating in TrumpRx.